Puma Bio: Sifting Through The Q4 Earnings Report (NASDAQ:PBYI) | Seeking Alpha
Fight against cancer : our therapeutic responses | Pierre Fabre
Fight against cancer : our therapeutic responses | Pierre Fabre
Puma Biotechnology, Pierre Fabre enter into Exclusive License Agreement
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in
Fight against cancer : our therapeutic responses | Pierre Fabre
Pierre Fabre & NERLYNX commercialisation | Nerlynx
Partners of the Pierre Fabre Group: from health to beauty
Puma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China | Business Wire
Fight against cancer : our therapeutic responses | Pierre Fabre
Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a Woe
CANbridge Pharmaceuticals and Puma Biotechnology Agree to Terminate NERLYNX® License Agreement and Settle Arbitration | Business Wire
Partners of the Pierre Fabre Group: from health to beauty
Pierre Fabre and ValenzaBio collaborate on anti-IGF-1R antibody for TE
Puma regains China rights to Nerlynx and amends deal with Fabre
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Blue March: Pierre Fabre supports colorectal cancer awareness month
Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a Woe
Puma and CANBridge cancel licensing deal for $20m
Pierre Fabre étend sa collaboration avec Puma Biotechnology
Puma regains China rights to Nerlynx and amends deal with Fabre
Puma Biotech Expands Pierre Fabre License to Add Countries
Puma Biotechnology | Evaluate
